Filing Flows › Lexicon Pharmaceuticals (LXRX) › Q3 2025
Lexicon Pharmaceuticals (LXRX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Lexicon Pharmaceuticals (LXRX) reported revenue of $14.2M for the third quarter 2025 (Q3 2025), +710% from a year earlier and -51% from the quarter before. Operating margin was -85.9%, net loss $12.8M (90.0% of revenue).
Lexicon Pharmaceuticals, Q3 2025: revenue $14.2M (+710% year over year), operating margin -85.9%, net loss $12.8M, operating cash flow −$23.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.2M | -51% | +710% |
| Operating profit | −$12.2M | -426% | — |
| Net earnings | −$12.8M | -493% | — |
| Operating cash flow | −$23.8M | -240% | — |
What changed
Revenue was $14.2M in Q3 2025, up 710% year over year and down 51% from the previous quarter. License was the largest line at 93% of revenue. Product declined 42%.
Operating costs exceeded revenue by $12.2M, an operating margin of -85.9%. Total costs fell 60% while revenue rose 710%. The quarter ended with a net loss of $12.8M, after a profit of $3.3M the previous quarter.
Operating cash flow was −$23.8M. Non-cash charges added back $151K of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items used $14.7M.
Questions
What was Lexicon Pharmaceuticals' revenue in the third quarter 2025?
Lexicon Pharmaceuticals (LXRX) reported revenue of $14.2M for the third quarter 2025 (Q3 2025), +710% from a year earlier and -51% from the quarter before.
Was Lexicon Pharmaceuticals profitable in the third quarter 2025?
Operating loss was $12.2M (-85.9% of revenue) and net loss $12.8M.